Trial record 6 of 52 for:    Open Studies | "Spondylitis, Ankylosing"

BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Boehringer Ingelheim
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: January 24, 2014
Last updated: July 23, 2014
Last verified: July 2014

The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 in adult patients with AS, in order to provide clinical proof of concept and to select dose (s) for confirmatory clinical trials.

Condition Intervention Phase
Spondylitis, Ankylosing
Drug: Placebo
Drug: BI 655066
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Assessment of Spodyloarthritis International Society (ASAS) 40 response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Ankylosing Spondylitis Disease Activity Score (ASDAS) score as compared to baseline (Key Secondary) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Assessment of Spodyloarthritis International Society (ASAS) 5/6 response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Assessment of Spodyloarthritis International Society (ASAS) remission criteria [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Assessment of Spodyloarthritis International Society (ASAS) 20 response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Assessment of Spodyloarthritis International Society (ASAS) 40 response [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change in Bath Ankylosing Spondylitis Disease Activity Score (BASDAI) score as compared with baseline [ Time Frame: Week 12 ] [ Designated as safety issue: No ]

Estimated Enrollment: 160
Study Start Date: January 2014
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Arm 4
s.c. injections placebo
Drug: Placebo
Experimental: Arm 1
BI 655066 s.c.
Drug: BI 655066
Low Dose
Experimental: Arm 2
BI 655066 s.c.
Drug: BI 655066
Medium Dose
Experimental: Arm 3
BI 655066 s.c.
Drug: BI 655066
High Dose


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Male and female patients
  • Age >= 18 years and =< 70 years.
  • Definite AS based on the modified New York criteria (1984)
  • Documented disease duration > 3 months at screening
  • Active disease at screening, defined as:

    • BASDAI score (0-10) >= 4, AND
    • Spinal pain level assessed by patient on numerical rating scale (NRS) (0-10) >= 4 (2nd question from BASDAI will be used here)
  • Have either a documented inadequate response for axial symptoms to 30 days of optimal daily doses of at least two non-steroidal anti-inflammatory drugs (NSAIDs), or documented intolerance to NSAIDs

Exclusion criteria:

  • Radiographic evidence of total ankylosis of the spine at screening or before (spinal X-Ray examinations at screening visit/ during screening period are not mandatory - see footnote 12 from Flow-Chart 1).
  • Patient previously treated with any biological immunomodulating agent for AS, either licensed or experimental
  • Previous or current participation in a clinical trial testing an investigational drug for AS
  • Usage of any investigational drug within 30 days prior to randomization or the planned use of an investigational drug during the course of the actual study
  • Active uveitis or inflammatory bowel disease at screening
  • Diagnosed psoriatic arthritis at screening, satisfying the modified New York criteria
  • Patients who had received intraarticular injection(s) with corticosteroids within 4 weeks prior to screening visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02047110

Contact: Boehringer Ingelheim Call Center 1-800-243-0127

  Show 49 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim Identifier: NCT02047110     History of Changes
Other Study ID Numbers: 1311.8, 2013-003666-13
Study First Received: January 24, 2014
Last Updated: July 23, 2014
Health Authority: Belgium: Federal Agency for Medicinal and Health Products
Finland: Finnish Medicines Agency
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Paul-Ehrlich-Institut
Hong Kong: Department of Health
Italy: Ethics Committee
Korea: Ministry of Food and Drug Safety
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Spain: Spanish Agency of Medicines
Taiwan : Food and Drug Administration
United States: Food and Drug Administration

Additional relevant MeSH terms:
Spondylitis, Ankylosing
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Arthritis processed this record on August 01, 2014